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ABSTRACT  
Objective: The study aimed to describe the prescription pattern of cardiovascular and/or anti-diabetic drugs and adherence to the World Health 
Organization (WHO) prescribing indicators in Abuja District Hospitals.  
Methods: This descriptive retrospective study was carried out in Asokoro and Maitama District Hospitals Abuja. One thousand and nine 
prescriptions that contained a cardiovascular drug (CVD) and/or anti-diabetic drug issued between June 2017 and May 2018 from the Medical 
Outpatient Department were analyzed. Data were collected from the pharmacy electronic database, prescription pattern and adherence to WHO 
prescribing indicators were assessed. The analysis was done using descriptive statistics. Results were presented as percentages, means, and 
standard deviations. 
Results: The frequency of treatment was higher among women (58.8%) and the age group of 41–60 (54.8%). The average number of drugs 
prescribed was 3.3±1.6: the percentage of drugs prescribed in generic was (64%) and (78.8%) were from the Essential Drug List (EDL). Calcium 
Channel Blockers (CCB, 71.7%) and Biguanides (B, 92.4%) were the most prescribed CVD and anti-diabetic drug. The majority of the CVD (74.5%) 
and diabetes (63.6%) patients were on combination therapy. The most frequent CVD combination was CCB plus Angiotensin-Converting Enzyme 
Inhibitors/Angiotensin Receptor Blockers (29.7%). Compared to men, the proportion of females taking one or more CVD (61.3%) or antidiabetic 
(56.4%) was higher. 
Conclusion: The prescribing indicators are not optimal in Abuja district hospitals. Women received more treatment for cardiovascular and diabetes 
diseases than men while the age range of 41-60 was more treated than other age groups.  
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Non-Communicable Diseases (NCDs) is a global health threat 
affecting men and women in their most productive years. In 2016, 
NCDs were responsible for more than 70% of the global deaths [1]. 
Presently an epidemiological transition has taken place in lower-
middle-income countries [2] where NCDs constitute more than 60% 
of deaths in the region [1]. Cardiovascular diseases (CVDs) and 
diabetes were responsible for more than 50% of mortality due to 
NCDs in lower-middle-income countries [1]. Global Health Estimates 
in 2016 showed that CVDs and diabetes accounted for 29% of Years 
of Life Lost and 40.7% of deaths due to NCDs among Nigerian men 
and women [1, 3]. In Nigeria, the prevalence of CVDs has not been 
established but existing evidence shows an increase in the 
prevalence of risk factors like hypertension and obesity [4, 5]. The 
prevalence of diabetes in Nigeria ranges between 4.04% [6] to 
5.77% [7]. With these increases, hospital consultations and 
attendant drug prescription which is an integral part of the 
management of CVDs and diabetes are likely to assume an upward 
and different trend. Consequently, there is a need to evaluate the 
quality of care received by the patients in terms of prescription. 
Existing evidence suggests that Cardiovascular (CV) drugs and anti-
diabetic drugs are among the highest therapeutic drug class 
prescribed in the outpatient [8, 9]. The WHO recognizes the 
investigation of prescription as an objective method to describe drug 
use in health facilities [10]. Evaluation of prescription pattern and 
prescribing indicators can describe the prevailing prescription trend 
and assess the extent of rational drug use. Drug use study can be 
used to evaluate the healthcare needs of people according to age and 
sex at various levels of the health care system and this may 
contribute to adjustments in the drug policy of a country's health 
care system. This is particularly important in Nigeria where drug 
products exist both as a single agent and fixed-dose combinations. 
The district hospitals in FCT are at the center of the provision of care 
for CVD and diabetes, and make a good site for an investigation into 
the prescription pattern. 
There are variations in the reports of prescription patterns for CVDs 
and diabetes drugs, studies have reported Calcium Channel Blockers 
(CCB) [11–13] or Angiotensin-Converting Enzyme Inhibitor (ACEI) 
[14, 15] as the most utilized class of antihypertensive drugs. Other 
studies have documented diuretics [16, 17] as the most utilized CVD. 
Reports on the prescription pattern of anti-diabetics documented 
sulphonylureas [14,18] or metformin [19] as the most utilized class 
of diabetes drug. However, inherent differences exist in prescription 
patterns across countries and even among similar health institutions 
of the same country, which necessitates more information on the 
pattern of use of drugs for these diseases. With more drugs being 
registered in Nigeria, there is always a gap in the knowledge of the 
use of drugs. Also, the guidelines on the management of CVDs and 
diabetes are not gender or age-specific on classes of a drug to use 
and it is not clear whether the prescription is the same for different 
gender and age group. This study was undertaken to assess 
prescription patterns for CVD and diabetes and adherence to WHO 
prescribing indicators in two secondary health institutions. 
MATERIALS AND METHODS 
Methods 
Study design and setting 
This retrospective study was conducted in Abuja District Hospitals 
in Nigeria from June to August 2018. Abuja is the Federal Capital 
Territory (FCT). FCT has thirteen district hospitals that are 
established and managed by the FCT Hospital Management Board. 
The operations of clinical services in these hospitals differ to some 
extent as they do not all have the same type of specialists. Two 
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district hospitals were purposively selected out of the thirteen 
district hospitals. Asokoro and Maitama District Hospitals were 
chosen because they maintain an accessible electronic medical 
database that covers the period of the study and runs a Medical 
Outpatient Department (MOPD). Information in the database of 
pharmacy department include patient identification number, date of 
birth, date of prescription, sex, occupation, drugs prescribed, clinic 
where the prescription is being generated from, source of funding 
for the treatment, The Medical Outpatient Department (MOPD) 
holds a CV and diabetes clinic on two separate days of the week.  
A sampling of the prescriptions 
Using the information provided from the pharmacy records on the 
number of cardiovascular (CV) drugs and anti-diabetics dispensed 
for the period, the total prescriptions containing a cardiovascular 
drug and/or anti-diabetic were estimated to be 7279. The 
consultation days and prescriptions containing cardiovascular (CV) 
and/or anti-diabetic drugs were selected using systematic random 
sampling. The two consultation days were listed and alternate days 
were selected. On each day, every fourth prescription from MOPD 
was selected. Prescriptions included in the study were those 
containing at least one CV and/or anti-diabetic drug prescribed from 
MOPD for patients above 18 y. cardiovascular drugs are those used 
for hypertension and heart failure. Excluded prescriptions are those 
written without sex, age. There was no replacement.  
Data collection 
Data were collected using a modified WHO prescribing indicator 
data collection form. The age, sex, occupation, source of funding, 
cardiovascular drugs, anti-diabetic drugs, and other drugs in the 
prescription were collected. According to WHO [10] guide for 
investigating drug use pattern in facilities, at least 600 prescriptions 
must be sampled. A total of 1009 prescriptions (491 and 518) from 
Maitama and Asokoro hospitals respectively were systematically 
sampled out to assess the prescription pattern and WHO prescribing 
indicators. Ethical approval was received from FCT and Asokoro 
District Hospital Health Research Ethics Committee with the 
approval number FHREC/2018/01/48/26-04-18 and FCTA/HHSS/ 
ADH/EC/0055/18 respectively. An approval letter was also given by 
Maitama District Hospital.  
Analysis of data  
The data were coded into Statistical Package for the Social Sciences 
for Window (IBM SPSS version 21) and subsequently analyzed using 
descriptive statistics. Association between prescriptions, gender, 
and age were tested with chi-square. P-value<or = to 0.05 was 
considered statistically significant. Results were expressed in 
frequencies, percentages, numbers, means and standard deviations. 
To evaluate the prescription pattern, the number of cardiovascular 
and antidiabetic drugs was determined for each prescription. The 
drugs were classified according to the Anatomical Therapeutic 
Chemical (ATC) code. The cardiovascular drugs include calcium 
channel blockers-C08, agents acting on the rennin angiotensin 
system-C09, diuretics-C03, beta-blocking agents-C07, centrally 
acting drugs-C02A, and cardiac therapy-C01. The anti-diabetic was 
classified into biguanides-A10BA, sulfonylureas-A10BB, dipeptidyl 
peptidase (DPP-4) inhibitors-A10BH and insulin-A10A. The 
prescription pattern for cardiovascular and anti-diabetic drugs was 
evaluated according to gender and age. The percentage of 
cardiovascular and anti-diabetic drugs prescribed in generic and 
from the Essential Drug List (EDL) was also assessed. Nigeria and 
FCT EDL were utilized. The WHO prescribing indicators as 
recognized by the World Health Organization/International 
Network for Rational Use of Drugs (WHO/INRUD) were analyzed for 
the prescriptions. The prescribing indicators include the average 
number of drugs per prescription, percentage of drugs prescribed by 
generic name, percentage of encounters with an antibiotic 
prescribed, percentage of prescriptions with an injection prescribed, 
percentage of drugs prescribed from essential drug list. Other 
indicators analyzed were the average number of cardiovascular and 
anti-diabetic drugs per prescription, percentage of cardiovascular or 
anti-diabetic drug prescribed in generic and percentage of 
cardiovascular or anti-diabetic drug prescribed from EDL. 
RESULTS 
Demographic characteristics 
The mean age of the patients was 52.6±12.5 similar in both genders 
(range 19-95 y). Prescriptions for females constituted 593 (58.8%). 
Approximately 55% of the prescription was written for patients 
between 41-60 y (table 1). 
 
Table 1: Age and sex distribution 
Variables Males Females Total 
Number (%) 416 (41.2) 593(58.8%) 1009(100%) 
Age     
mean±SD 52.64±12.2 52.51±12.8   
19-40 73(7.2) 116(11.5) 189(18.7%) 
41-60 225(22.3) 328(32.5) 553(54.8%) 




The average number of drugs per prescription was 3.3±1.6, with a 
range of 1-9 drugs. The commonest number of drugs was 3 drugs, 
while the least was 9 drugs. Percentage of drug prescribed in 
generics was 64% and 78.8% were from Nigeria Essential Drug List 
(EDL) or FCT EDL. Prescriptions for antibiotics and injections were 
7% and 5.7% respectively. Insulin constituted 65.5% of the 
injections prescribed. Prescriptions for cardiovascular and anti-
diabetic drugs were (855) 84.7% and 335 (33.2%) respectively, 
while 180 (17.8%) of the prescriptions contain cardiovascular and 
anti-diabetic drugs. The total number of cardiovascular drugs 
prescribed was 1728 (2.0/prescription) while anti-diabetic was 573 
(1.7/prescription). Among all prescribed cardiovascular and 
diabetes medicines, s-amlodipine, irbesartan, enalapril, perindopril, 
nebivolol, torasemide indapamide, and sitagliptin were neither in 
Nigeria nor FCT EDL. Percentage of cardiovascular drug and anti-
diabetic drugs prescribed in generics was 74.6% and 15.5% 
respectively. Prescriptions paid from insurance were 7.2%. The 
prescribing indicators are summarized in table 2. Other drug classes 
most prescribed were antiinfectives 18.4%, antiplatelets 17.9%, 
antipyretics/analgesics 15.5%, multi-vitamins/supplements 14.6%, 
lipid regulating drugs 8.2%, gastrointestinal drugs 8.1% and 
anxiolytics/antidepressant 5.8%. 
Percentage prescription of cardiovascular and anti-diabetic 
drugs 
The frequency of use of the CVD was Calcium Channel Blockers (CCB, 
71.7%), Angiotensin-Converting Enzyme Inhibitors/Angiotensin 
Receptor Blockers (ACEI/ARB, 67.8%), Diuretics (D, 43.6%), Beta 
Blockers (BB, 7.2%), Cardiac Glycosides (CG, 6.3%) and Centrally 
Acting (CA, 5.9%). Considering the specific agents, Amlodipine was the 
most prescribed CVD, with a frequency of 486 (56.9%), followed by 
Lisinopril 353 (41.3%), hydrochlorothiazide 249 (24.7%) and 
telmisartan 133 (15.6%). The least prescribed drug was nebivolol 
(0.1%), (table 3). Biguanide (B) was the commonly prescribed anti-
diabetic (92.4%) followed by Sulphonylureas (SU, 56.5%) while 
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Dipeptidyl peptidase (DPP-4) inhibitors (11.1%) were the least 
prescribed (table 4). For the CVD, CCB (11.6%), ACEI/ARB (7%), D 
(4.7%), BB (1.2%) and CA (1.1%) were prescribed as monotherapy. 
The most occurring combination therapy was CCB (38%) in 2 drug 
therapy; diuretic (22.5%) in 3 drug therapy; BB and diuretics (1.8%) 
in 4 drug therapy. Only (0.1%) 5 drug combination was observed. 
Examination of the anti-diabetic drugs revealed that biguanides, 
(28.7%), Insulin (4.5%) and Sulphonylurea (3.3%) were prescribed as 
monotherapy. Biguanide was the most frequent drug in combination 
therapy; 2-drugs (56.5%), 3-drugs (6.9%), (table 5). The commonest 
CVD combination observed was CCB plus ACEI/ARB (29.7%), followed 
by CCB plus diuretic (5.7%). In 3-drug combination, CCB plus 
ACEI/ARB plus D (17.8%) was seen followed by ACEI/ARB plus D plus 
CG (2.3%). Biguanides plus sulphonylureas (47.5%) were the 
commonly used 2 drugs combination. Sixty-one (6%) of the CV and 46 
(4.5%) of anti-diabetic prescriptions were fixed-dose combinations. 
  
Table 2: Prescribing indicators 
Variables (M±Sd) 
Average number of drugs  3.3±1.6 
Cardiovascular drugs  2.02±0.8 
Females  2.03±0.8 
Males  2.01±0.7 
Diabetic drugs  1.71±0.6 
Females  1.74±0.6 
Males  1.68±0.6 
% Generics  64 
% Cardiovascular  74.6 
% Diabetes  15.5 
% Antibiotics  7 
% Injections 5.7 
% Essential drug list  78.8 
% Cardiovascular  97 
% Diabetes  98 
M±sd = mean±Standard deviation 
 
Table 3: Prescription pattern of cardiovascular drugs 
Drug class Drug name ATC code  N  (%) 
CCB  C08 612 71.7 
 Amlodipine  C08CA01 486 56.9 
 Nifedipine C08CA05 116 13.6 
 S-amlodipine N/A  10  1.2 
ACEI/ARB  C09 579 67.8 
 Lisinopril C09AA03 353 41.3 
 Enalapril C09AA02 3 0.4 
 Ramipril C09AA05  19  2.2 
 Perindopril C09AA04 2  0.2 
 Telmisartan C09CA07 133  15.6 
 Valsartan C09CA03 35 4.1 
 Losartan C09CA01 32 3.7 
 Irbesartan C09CA04 2 0.2 
Diuretics  C03 526 43.6 
 Hydrochlorothiazide C03AA03 249 20.6 
 Spironolactone C03DA01 89 7.3 
 Furosemide C03CA01 79 6.5 
 Amiloride C03DB01 77 6.4 
 Torasemide C03CA04 25 2.1 
 Indapamide  C03BA11 9 0.7 
Beta-blocker  C07 60 7.1 
 Atenolol C07AB03 32 3.8 
 Bisoprolol C07AB07 20 2.4 
 Propranolol C07AA05 7 0.8 
 Nebivolol C07AB12 1 0.1 
Centrally acting Methyldopa C02AB 50 5.9 
Cardiac glycoside Digoxin C01AA05 54 6.3 
CCB = Calcium Channel Blockers, ACEI = Angiotensin-Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, N/A = Not Available, N = 
Number of prescriptions 
 
Prescription of the cardiovascular and diabetic drug by gender 
and age 
The frequency of treatment for cardiovascular diseases (61.3%) 
and diabetes (56.4%) was higher in females. The proportion of 
patients treated with one (15.8% vs. 9.7%), two (29.4 vs. 19.5) 
or three (14.7% vs. 9%) CVD was higher in females than men. 
Only (0.3%) men received four anti-diabetic drugs. Percentage 
use of CV and anti-diabetic drug prescription by gender are 
summarized in fig. 1 and fig. 2, respectively. The prescriptions 
for CCB (P = 0.014), ACEI/ARB (P= 0.02), centrally acting drugs 
(p=0.001) and diuretics (P = 0.05) were significantly higher in 
females. The percentage of BB prescription was higher in 
females but no significant difference. For diabetic drugs, higher 
proportions of males received a prescription of sulphonylureas 
and biguanides, while more females received DPP-4 inhibitors 
and insulin (table 6).  
Table 7 compares the use of CVD and anti-diabetic drug classes by age. 
The proportion of prescriptions for CVD and the anti-diabetic drug 
was higher among the ages of 41-60. The use of CCB (P=<0.001), 
ACEI/ARB (P=<0.001), diuretics (P=<0.001), centrally acting drugs 
(P=<0.001), metformin (P=<0.001) and insulin (P=<0.001) was 
significantly higher in people within the age of 41-60. 
Osuafor et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 9, 21-27 
24 
Table 4: Prescription pattern of anti-diabetic drugs 
Drug class Drug name ATC code  N  (%) 
Biguanide Metformin A10BA02 309 92.4 
Sulphonylurea  A10BB 191 56.5 
 Glimepiride A10BB12 173 51.2 
 Glibenclamide A10BB01 18 5.3 
Insulin   A10A 38 11.4 
 BI 30/70 A10AD30 31 9.3 
 Soluble insulin A10AB01 4 1.2 
 Glargine  A10AE04 3 0.9 
DPP-4 I  A10BH 35 11.1 
 Vildagliptin A10BH02 24 7.6 
 Sitagliptin A10BH01 11 3.5 
BI 30/70 = Biphasic isophane insulin 30% soluble 70% isophane, DPP–4I = Dipeptidyl Dipeptidase-4-Inhibitors N= Number of prescriptions 
 
Table 5: Proportion of drug class as monotherapy and combination therapy N (%) 
Drug class 1-drug  2–drugs  3-drugs 4–drugs 5–drugs 
CCB 99 (11.6)  325 (38) 174 (20.4) 13(1.6) 1 (0.1) 
ACEI/ARB 60 (7.0)  317 (37.1) 186 (21.8) 15(1.8) 1 (0.1) 
Diuretic 40 (4.7)  122 (14.2) 195 (22.8) 15(1.8) 1 (0.1) 
Beta-Blocker 10 (1.2)  28 (3.3) 16 (2) 5(.6) 1 (0.1) 
Centrally acting  9 (1.1)  20 (2.4) 14 (1.6) 6(.7) 1 (0.1) 
Digoxin -  24 (2.8) 24 (2.8) 6(.7) - 
Antidiabetic      
Biguanides 96 (28.7) 189 (56.5) 23 (6.9) 1 (0.3) - 
Sulphonylureas 11 (3.3) 159 (47.5) 18 ((5.4) 1 (0.3) - 
Insulin 15 (4.5)  13 (3.9)  9 (2.7) 1 (0.3) - 
DPP-4I -  17 (5.1) 19 (5.7) 1 (0.3) - 
CCB = Calcium Channel Blockers, ACEI = Angiotensin Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, DPP–4I = Dipeptidyl 
Dipeptidase-4-Inhibitors., N= Number of prescriptions 
 
 
Fig. 1: Percentage of CVD use by gender, CVD= Cardiovascular drug 
 
Table 6: Pattern of prescription of cardiovascular and diabetes drugs by gender N (%) 
Therapeutic group Drug class Females Males P-value 
CVD CCB 364(61.4) 248(59.6) 0.014* 
 ACEI/ARB 350(59) 229(55) 0.002* 
 Diuretics 227(38.3) 146(35.1) 0.050* 
 Beta-blocker 43(7.3) 17(4.1) 0.088 
 Centrally acting 41(6.9) 9(2.2) 0.001* 
 Digoxin 39(6.6) 15(3.6) 0.039* 
Antidiabetics  Sulphonylureas 105(17.7) 86(20.7) 0.296 
 Biguanides 172(29) 137(32.9) 0.183 
 DPP-4 I 25(4.2) 10(2.4) 0.490 
 Insulin 26(4.4) 12(2.9) 0.431 
CCB = Calcium Channel Blockers, ACEI = Angiotensin-Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, DPP–4I = Dipeptidyl 
Dipeptidase-4-Inhibitors, N = Number of prescriptions, * = P significant at ≤ 0.05 
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Fig. 2: Percentage use of antidiabetic drug by gender 
 
Table 7: Pattern of prescription of cardiovascular and diabetic drugs by age N (%) 
Therapeutic group Drug class  19-40 41-60 >60 P value 
CVD CCB 118 (19.3) 339(55.4) 155(25.3) <0.001* 
 ACEI/ARB  90 (15.5) 314(54.2) 175(30.2) <0.001* 
 Diuretics  71(19) 198(53.1) 104(27.9) <0.001* 
 Beta blocker  13(21.7) 34(56.7) 13(21.7) 0.836 
 Centrally acting  21(42) 25(50) 4(8) <0.001* 
 Digoxin  10(18.5) 24(44.4) 20(37) 1.71 
Anti-diabetic Sulphonylureas  14(7.3) 114(59.7) 63(33) 0.009 
 Biguanides  24(7.8) 181(58.6) 104(33.7) <0.001* 
 DPP-4 Inhibitors  1(2.9) 21(60) 13(37.1) 0.658 
 Insulin  10(26.3) 24(63.2) 4(10.5) <0.001* 
CCB = Calcium Channel Blockers, ACEI = Angiotensin-Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, DPP–4I = Dipeptidyl 
Dipeptidase-4-Inhibitors, N = number of prescriptions, * = P significant at ≤ 0.05 
 
DISCUSSION 
This present study assessed the prescribing indicators and 
prescription patterns for NCDs (CVDs and diabetes) medicines in the 
outpatient clinic. Prescription reflects how the clinician interprets the 
patient condition, plans for the management and the nature of the 
healthcare system in the country. The prevalence of treatment was 
higher among women (58.8%), which has been documented by 
previous reports in Nigeria 59.2% [19] 57.4% [20] and other countries 
Korea 53. 6% [21] and India 55.48% [11]. However, other studies 
reported a higher treatment rate in men [12, 22]. Our report might 
relate to the recent report of the high prevalence of hypertension and 
obesity among women in Nigeria [23]. The results indicated that most 
of the patients were in the age range of 41-60, which is consistent with 
the study by Krishna et al. [22]. This shows that CVDs and diabetes 
affect people in the most productive years of their lives.  
Our results showed the average number of drugs per prescription to 
be 3.3, which is similar to 3.4 reported in Pakistan [24] but higher 
than the ideal WHO standard of 1.6-1.8 [10] and 2.6 [19] reported in 
Southeastern Nigeria. However, higher values have been reported in 
Southwest Nigeria 3.9 [25], 5.8 [26], India 5.64 [11], 7.56 [15], 
Pakistan 4.63[14]. The high number of drugs in our study is 
probably due to the type of patient prescription included in this 
study. Already, guidelines on the management of CVD recommend 
combining drugs from different pharmacological classes to prevent 
morbidity associated with CVD [27] and the diabetic patient often 
requires an additional drug to achieve glycaemic control [28]. The 
fixed-dose combination is recommended to reduce pill burden but 
usually comes at a higher cost than two separate products [29]. In 
Nigeria, health insurance is not yet common, so the benefit of the pill 
burden reduction is usually weighed carefully against the cost. For 
instance, in our study, a fixed-dose combination was seen in only 6% 
and 4.6 % of CV and diabetic prescription respectively. Also, most 
patients with CVD and diabetes are known to have other conditions 
that will require treatment. The average number of CV drugs per 
prescription was 2.0, similar in both gender and close to previous 
reports on antihypertensive drugs in Nigeria 2.25 [16], 2 [30]. In 
contrast, a lower value was reported in South India at 1.78 [12]. The 
average number of diabetic drug per prescription was 1.7, also 
similar in both gender and consistent with the report of a previous 
study on anti-diabetic prescription in Southern Nigeria [20]. The 
result is expected as most of the prescription contains at least two 
CV or anti-diabetic. The generic prescription in this study 64% for all 
drugs, 74.6% CV drugs, and 15.5% for diabetic drugs are lower than 
the WHO standard 100% and differ from reports in Nigeria and 
other countries. Higher values have been reported in Nigeria 72.2% 
[19] Pakistan 71.6% [24], India 89.2% [11], Ethiopia 97%. [31] 
However, lower generic prescription was recorded in Nigeria 42.7% 
[32], Pakistan 56% [33]. Southern India 2.5% [34], 19.4% [35]. It is 
surprising that generic prescription was not optimal in our study 
especially the diabetic drugs, as the hospitals are established and 
managed by the government. Generic prescribing encourages 
stocking of various brands which will improve accessibility to the 
medicines. Again generic prescription leads to clarity of information 
among the health professionals [36]. The poor generic prescribing 
may be attributed to physicians' doubt towards prescribing low-cost 
generic medicines for hypertensive and diabetic patients [37].  
The percentage of injections 5% in this study is within WHO ideal 
value and similar to 4% [32] reported in Nigeria. In contrast, lower 
values have been reported in other similar studies in India 3.98% 
[11]. This is possible as CV injectable drugs are mostly used in 
emergency and inpatients. Insulin constituted a large percentage of 
the injections prescribed which is supported by the report of Adibe 
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et al. [19]. The percentage of encounters with antibiotics was 7% 
higher than 1.7% [19] reported in southern Nigeria but lower than 
another Nigeria study 26.8% [32]. However, higher values have been 
reported in Ethiopia 58% [38] 82.5% [31] Pakistan 48.9% [24]. This 
is expected as patients in our study are specialized, unlike the other 
studies that included prescriptions from all departments. 
The percentage of drugs prescribed from EDL in this study was 
78.8% which is lower than the WHO ideal value of 100%. Other 
studies recorded higher prescription from EDL Nigeria 94% [32], 
Ethiopia 92% [31], Pakistan 98.8% [33], India 99.8% [34]. Most of 
the CV (97%) and diabetic (98%) drugs prescribed are on the EDL. 
Prescription of multivitamins, supplements, and analgesics 
constituted most of the drugs that were not on EDL. We draw 
attention to the use of multivitamins and supplements, as their use 
exceeded the use of lipid regulating drugs which are considered 
useful for cardiovascular and diabetic patients. 
There was a high prescription of CCB, particularly amlodipine in FCT 
district hospitals. This was reported in some other studies 
[11,12,39,40] while CCB has been reported as least prescribed [22, 
41]. Agents that act on the renin-angiotensin system hold a good 
share of the prescription, with Lisinopril and Telmisartan leading in 
the class similar to other studies [15,41]. Other Nigeria study 
reported diuretic as most utilized [16, 17, 30]. Our report reflects a 
shift from the traditional prescription of diuretics in Nigeria. This is 
not surprising given the report that CCB either alone or in 
combination with other drugs is not inferior to diuretics in reducing 
cardiovascular effect [27,42]. Also, a diuretic is known to affect 
glucose homeostasis and lipid profile [27] this might have favored 
the use of CCB and drugs that act on the renin-angiotensin system in 
our study as it included diabetic patients. Over the years, a low price 
must have favored the use of diuretics, but with many generic CCB 
products being available, it is possible that the cost benefits of 
diuretics are wearing out. Perindopril and Nebivolol are relatively 
new in Nigeria market which might account for their low 
prescription. The low use of enalapril is surprising as it has been in 
Nigeria for a long time, though it is not included in EDL, a 
recommended ACEI for patients with hypertensive heart disease. 
Even though Amlodipine was the most single-agent prescribed, we 
noted that Lisinopril and telmisartan combined took the same share 
of prescription with amlodipine. The high use of renin antagonists in 
these hospitals was unexpected because they are not recommended 
for hypertensive black patients [27]. On the other hand, they are 
known to confer renal protection for diabetic patients which might 
have prompted their use [27]. 
Biguanides were the mostly prescribed anti-diabetic as a single 
agent and in combination with other drugs, which is consistent with 
Nigeria's studies [19,39]. This is expected as metformin has been 
established to lower cardiovascular risk and confer better survival 
to diabetic patients compared to other anti-diabetics [43]. 
Metformin is also known to promote weight loss, which is beneficial 
in type 2 diabetic patients. DPP-4-inhibitors were the least 
prescribed which contrasts [19,20,39]. Their low prescription might 
be attributed to their recommendation as add on therapy and also 
they are new in the Nigerian market.  
In our sample, a small proportion 22.5% of the patient was treated 
with monotherapy, this is supported by reports from Nigeria 2.5% 
[44], 20% [45] and India 27.7% [22]. In contrast, an Indian study 
[46] reported most CVD patients to be treated with monotherapy 
and Patel et al. [47] reported the use of monotherapy to treat 
diabetic patients. Our study is consistent with recommendations on 
the use of combination drugs from more than one class to manage 
CVD and diabetes [27,28]. Also, lower doses of different drugs 
ensure a better safety profile than a higher dose of one drug [27]. 
Besides, the study combined CV and diabetic drug which suggest 
that some patients have both conditions and must require more than 
one drug for compelling indication. 
Considering gender difference in the use of CVD drugs, the use of 
CCB, ACEI/ARB and diuretics were significantly higher in women, 
which is similar to a US [48] report. However, another study [12] 
reported no significant difference in genders in the use of CVD drugs. 
Thiazide diuretic has been reported to adversely affect men sexually 
[27], which might contribute to its low prescription in men. Gender 
difference in the use of CVD is still unclear. The gender difference in 
the use of antidiabetics was not significant, even though there is a 
high proportion of metformin and sulphonylureas prescribed for 
men, which is consistent with a Nigeria [20] report. 
Regarding age difference, the age range of 41-60 received a 
significantly higher proportion of most of the prescription of CVD 
and diabetic drugs, which is in agreement with a previous report in 
South Nigeria [20]. This is probably due to an increased number of 
consultations for people within that age, which suggests that people 
of that age suffer CVD and diabetes more. The use of insulin was low 
in people>60 y; this is possible because a high rate of hypoglycemia 
has been documented in the diabetic patient of that age group using 
insulin [49, 50].  
A limitation on this study is that information on compelling 
indication which might drive prescription was not gathered through 
the prescription and the study could not assess the clinical outcome 
that might affect the change of prescription. 
CONCLUSION 
The prescribing indicators (mean number of drugs, percentage of 
drugs prescribed in generic and percentage prescribed from EDL) 
are not in conformity with WHO/INRUD recommendation. Calcium 
channel blockers replaced thiazide diuretics as the most prescribed 
CV drug, while Metformin is the most prescribed antidiabetic drug. 
Compared to men, more women are receiving treatment for CVD and 
diabetes and the most productive age of 41-60 are being treated for 
CVDs and diabetes in FCT district hospitals. 
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